Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Not Applicable
Completed
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Drug: Insulin (Aspart Insulin [Novolog], Regular Insulin)
- Registration Number
- NCT00920725
- Lead Sponsor
- Rush University Medical Center
- Brief Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
age 18 or older
-
venous pH < 7.3 or arterial < 7.35
-
at least 2 of the following 3:
- serum HCO3 < 18/anion gap > 16
- serum glucose > 300 mg/dl
- serum acetone positive
Exclusion Criteria
- pregnant
- less than age 18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Subcutaneous Insulin Insulin (Aspart Insulin [Novolog], Regular Insulin) Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours IV Regular Insulin Insulin (Aspart Insulin [Novolog], Regular Insulin) Intravenous Regular Insulin 0.1 units/kg/hour Intravenous Novolog Insulin Insulin (Aspart Insulin [Novolog], Regular Insulin) Intravenous Novolog Insulin 0.1 units/kg/hour
- Primary Outcome Measures
Name Time Method Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate <0.6 q 2 hours Hours to achieve blood glucose less than 200mg/dl q 1 hour
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rush University Medical Center
🇺🇸Chicago, Illinois, United States